Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma

Luo,Weiqing; Ren,Zhigang; Gao,Sheng; Jin,Hailong; Zhang,Geer; Zhou,Lin; Zheng,Shusen

doi:10.3892/ol.2016.4079

Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma

Authors:
- Weiqing Luo
- Zhigang Ren
- Sheng Gao
- Hailong Jin
- Geer Zhang
- Lin Zhou
- Shusen Zheng
View Affiliations

Affiliations: Key Laboratory of Combined Multi‑Organ Transplantation, Ministry of Public Health, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Department of Gastrointestinal Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: January 7, 2016 https://doi.org/10.3892/ol.2016.4079
Pages: 1345-1352
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallbladder carcinoma (GBC) possesses a poor prognosis, which is primarily attributed to the lack of early and timely surgical intervention. Calpain-1 and glypican-3 have been implicated in the progression of various types of cancer. The present study aimed to detect the expression of calpain‑1 and glypican‑3 in GBC, and analyzed whether the expression levels of these proteins correlated with any clinicopathological variables. A total of 100 patients with GBC and 30 patients with cholecystitis who accepted surgical treatment were enrolled in the present study. Pathological and clinical data were obtained from all patients. The expression of calpain‑1 and glypican‑3 was detected in paraffin‑embedded tissues by immunohistochemistry. Calpain‑1 expression was manually assessed with an immunohistochemical H‑score with a slight modification. Glypican‑3 expression was assessed as negative and positive. The correlations between protein expression and clinicopathological characteristics, and the associations between the proteins were analyzed. All patients exhibited positive expression of calpain‑1. Notably, the high expression rate of calpain‑1 was significantly increased in patients with GBC, compared with patients with cholecystitis (32.0 vs. 6.7%; χ2=7.668; P=0.006), suggesting that calpain‑1 expression may be associated with progression from cholecystitis to GBC. In addition, the positive rate of glypican‑3 expression was 53.0% in patients with GBC and 63.3% in patients with cholecystitis, with no significant difference (χ2=0.997; P=0.318). Furthermore, the expression of calpain‑1 and glypican‑3 had no significant correlation with gender, age, degree of tumor differentiation and tumor‑node‑metastasis classification in patients with GBC. Notably, the expression of calpain‑1 and glypican‑3 displayed a significant positive correlation in patients with GBC (r=0.517; P<0.01), but a significantly negative correlation (r=‑0.856; P<0.01) in patients with cholecystitis. In conclusion, calpain‑1 expression may be associated with progression from cholecystitis to GBC. Combined detection of calpain‑1 and glypican-3 may be beneficial for prognosis assessment of GBC.

View Figures

View References

1	Hundal R and Shaffer EA: Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol. 6:99–109. 2014.PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Henson DE, Albores-Saavedra J and Corle D: Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 70:1493–1497. 1992. View Article : Google Scholar : PubMed/NCBI
4	Åndrén-Sandberg A and Deng Y: Aspects on gallbladder cancer in 2014. Curr Opin Gastroenterol. 30:326–331. 2014. View Article : Google Scholar : PubMed/NCBI
5	Sheth S, Bedford A and Chopra S: Primary gallbladder cancer: Recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 95:1402–1410. 2000. View Article : Google Scholar : PubMed/NCBI
6	Misra S, Chaturvedi A, Misra NC and Sharma ID: Carcinoma of the gallbladder. Lancet Oncol. 4:167–176. 2003. View Article : Google Scholar : PubMed/NCBI
7	Benyamin Y: The structural basis of calpain behavior. FEBS J. 273:3413–3414. 2006. View Article : Google Scholar : PubMed/NCBI
8	Storr SJ, Woolston CM, Barros FF, Green AR, Shehata M, Chan SY, Ellis IO and Martin SG: Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. Int J Cancer. 129:1773–1780. 2011. View Article : Google Scholar : PubMed/NCBI
9	Huang Y and Wang KK: The calpain family and human disease. Trends Mol Med. 7:355–362. 2001. View Article : Google Scholar : PubMed/NCBI
10	Kamei M, Webb GC, Young IG and Campbell HD: SOLH, a human homologue of the Drosophila melanogaster small optic lobes gene is a member of the calpain and zinc-finger gene families and maps to human chromosome 16p13.3 near CATM (cataract with microphthalmia). Genomics. 51:197–206. 1998. View Article : Google Scholar : PubMed/NCBI
11	Ho M and Kim H: Glypican-3: A new target for cancer immunotherapy. Eur J Cancer. 47:333–338. 2011. View Article : Google Scholar : PubMed/NCBI
12	Capurro MI, Xiang YY, Lobe C and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254. 2005. View Article : Google Scholar : PubMed/NCBI
13	Capurro MI, Xu P, Shi W, Li F, Jia A and Filmus J: Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell. 14:700–711. 2008. View Article : Google Scholar : PubMed/NCBI
14	Zittermann SI, Capurro MI, Shi W and Filmus J: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. 126:1291–1301. 2010.PubMed/NCBI
15	Feng M, Kim H, Phung Y and Ho M: Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer. 128:2246–2247. 2011. View Article : Google Scholar : PubMed/NCBI
16	Hsu HC, Cheng W and Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution. Cancer Res. 57:5179–5184. 1997.PubMed/NCBI
17	Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 10:6612–6621. 2004. View Article : Google Scholar : PubMed/NCBI
18	Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L and Singer G: Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol. 26:341–344. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zynger DL, Dimov ND, Luan C, Teh BT and Yang XJ: Glypican 3: A novel marker in testicular germ cell tumors. Am J Surg Pathol. 30:1570–1575. 2006. View Article : Google Scholar : PubMed/NCBI
20	Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK and Terracciano LM: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 129:899–906. 2008. View Article : Google Scholar : PubMed/NCBI
21	Saikali Z and Sinnett D: Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 89:418–422. 2000. View Article : Google Scholar : PubMed/NCBI
22	McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2:416–422. 2005. View Article : Google Scholar : PubMed/NCBI
23	Edge SB, Byrd DR, Compton CC, et al: Gallbladder. AJCC Cancer Staging Manual (7th). (New York, NY). Springer. 211–217. 2010.
24	Boutros C, Gary M, Baldwin K and Somasundar P: Gallbladder cancer: Past, present and an uncertain future. Surg Oncol. 21:e183–e191. 2012. View Article : Google Scholar : PubMed/NCBI
25	Srivastava K, Srivastava A and Mittal B: Potential biomarkers in gallbladder cancer: Present status and future directions. Biomarkers. 18:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wang YF, Feng FL, Zhao XH, Ye ZX, Zeng HP, Li Z, Jiang XQ and Peng ZH: Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 20:4085–4092. 2014. View Article : Google Scholar : PubMed/NCBI
27	Kulkarni S, Reddy KB, Esteva FJ, Moore HC, Budd GT and Tubbs RR: Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. Oncogene. 29:1339–1350. 2010. View Article : Google Scholar : PubMed/NCBI
28	Storr SJ, Lee KW, Woolston CM, Safuan S, Green AR, Macmillan RD, Benhasouna A, Parr T, Ellis IO and Martin SG: Calpain system protein expression in basal-like and triple-negative invasive breast cancer. Ann Oncol. 23:2289–2296. 2012. View Article : Google Scholar : PubMed/NCBI
29	Storr SJ, Pu X, Davis J, Lobo D, Reece-Smith AM, Parsons SL, Madhusudan S and Martin SG: Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. J Gastroenterol. 48:1213–1221. 2013. View Article : Google Scholar : PubMed/NCBI
30	Storr SJ, Zaitoun AM, Arora A, Durrant LG, Lobo DN, Madhusudan S and Martin SG: Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. BMC Cancer. 12:5112012. View Article : Google Scholar : PubMed/NCBI
31	Baudry M, Chou MM and Bi X: Targeting calpain in synaptic plasticity. Expert Opin Ther Targets. 17:579–592. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sawhney RS, Cookson MM, Omar Y, Hauser J and Brattain MG: Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: Identification of a novel signaling pathway. J Biol Chem. 281:8497–8510. 2006. View Article : Google Scholar : PubMed/NCBI
33	Storr SJ, Thompson N, Pu X, Zhang Y and Martin SG: Calpain in breast cancer: Role in disease progression and treatment response. Pathobiology. 82:133–141. 2015. View Article : Google Scholar : PubMed/NCBI
34	Moretti D, Del Bello B, Allavena G and Maellaro P: Calpains and cancer: Friends or enemies? Arch Biochem Biophys. 564:26–36. 2014. View Article : Google Scholar : PubMed/NCBI
35	Pan Z, Chen C, Long H, Lei C, Tang G, Li L, Feng J and Chen F: Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis. Mol Med Rep. 7:969–974. 2013.PubMed/NCBI
36	Song HH, Shi W, Xiang YY and Filmus J: The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 280:2116–2125. 2005. View Article : Google Scholar : PubMed/NCBI
37	Field MA, Cho V, Andrews TD and Goodnow CC: Reliably detecting clinically important variants requires both combined variant calls and optimized filtering strategies. PLoS One. 10:e01431992015. View Article : Google Scholar : PubMed/NCBI
38	Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N, et al: Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 15:7972015. View Article : Google Scholar : PubMed/NCBI